Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.
Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Doctor Anywhere Pte Ltd is a Singapore-based telehealth company that provides an online platform for health and wellness solutions. Established in 2016, the company specializes in video consultations, allowing patients to consult with licensed and registered doctors for various medical needs. Its digital platform offers on-demand healthcare services that are designed to be simple, seamless, and convenient, catering to the evolving lifestyle preferences of users. By integrating a range of health services, Doctor Anywhere enables patients to receive appropriate diagnoses, medication, and e-prescriptions, facilitating access to healthcare anytime and anywhere. The company aims to improve health outcomes through technology, addressing modern healthcare challenges and enhancing the overall patient experience.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
The BBI Group has been a trusted partner to some of the world’s leading diagnostic and healthcare organisations for over 25 years. Founded upon the success of the superior quality and performance of our gold reagents, our organisation has grown to incorporate 3 businesses delivering excellence in diagnostic assay development and manufacturing across a range of sectors, and the supply of consumer healthcare products.
PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, facilitating real-time online consultations. The platform also allows patients to order laboratory tests that can be conducted at home and helps them locate nearby hospitals and clinics. Additionally, HaloDoc provides access to licensed medical laboratory services and a medical delivery service known as ApotikAntar, further enhancing the convenience and accessibility of healthcare for its users.
Altasciences Clinical Research, encompassing Algorithme Pharma, Vince & Associates Clinical Research and Algorithme Pharma USA, is one of the early phase clinical research organizations (CROs) in North America. As a full-service CRO, we have extensive expertise in the execution of a wide range of Phase I/II clinical studies, especially complex trials in healthy normal volunteers and patient populations.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders associated with neuronal imbalance. The company's lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently undergoing Phase IIa clinical trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy, and a program for KCNT1 GOF epilepsy. The company engages in collaborations and licensing agreements with various partners, including RogCon Inc., Purdue Neuroscience Company, and Ionis Pharmaceuticals. Founded in 2015, Praxis Precision Medicines is headquartered in Cambridge, Massachusetts.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Private Equity Round in 2019
WCG is a prominent provider of regulatory and ethical review services for human research, focusing on enhancing the quality and efficiency of clinical studies. The company reviews new research protocols and offers a range of services including clinical and human gene therapy research, laboratory biosafety consulting, and solutions for human research protections. WCG also provides online learning resources, an electronic informed consent solution to streamline clinical processes, oncology review services, and a cloud-based platform for managing research activities. Serving a diverse clientele that includes large pharmaceutical companies, biotechnology firms, and contract research organizations, WCG is committed to accelerating the delivery of new treatments while upholding high standards of human subject protection. Founded in 2012 and headquartered in Princeton, New Jersey, WCG operates multiple locations across the United States and in Tokyo, Japan, and has established a strategic partnership with InformedDNA.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.
Founded in 2006, MDLive is a telehealth provider that offers online and on-demand healthcare services. The company connects patients with board-certified doctors through phone, video, and mobile applications, facilitating access to medical care without the need for in-person visits. Its cloud-based platform allows healthcare professionals and institutions to conduct virtual consultations, helping to ensure safe and efficient patient care while reducing the costs associated with emergency room and urgent care visits for non-emergency issues. MDLive serves a diverse range of clients, including hospitals, employers, payers, and physician practice groups, thereby enhancing the overall healthcare delivery system.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.
AMRA is an international medical technology company, the first in the world to transform MR images into precise body composition measurements using a cloud-based, computer-aided service.They collaborate with world-leading pharmaceutical organizations, biobanks and population cohorts, research institutions, hospitals, and clinics, aiding in the advancement of metabolic research and therapeutic application. With more accurate knowledge about our bodies, AMRA assists the world's medical leaders in predicting and preventing disease.
Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The company’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.
Minerva Surgical Inc. is a medical technology company focused on women's healthcare, specifically developing products to address abnormal uterine bleeding. The company's flagship product is The Minerva Endometrial Ablation System, designed to provide effective treatment options for this common condition. Founded in 2008, Minerva Surgical is based in California and aims to innovate within the field of gynecological treatments.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Spectranetics Corporation specializes in the development, manufacturing, marketing, and distribution of single-use medical devices designed for minimally invasive procedures in cardiovascular health. The company’s product offerings include various devices for vascular intervention, such as laser and aspiration catheters, scoring balloon catheters, and drug-coated balloon catheters, aimed at addressing arterial blockages in the legs and heart. Additionally, Spectranetics provides advanced lead management solutions, including excimer laser sheaths and associated accessories for the removal of pacemaker and defibrillator leads. The Stellarex DCB platform is also part of their portfolio, specifically targeting peripheral arterial disease. Spectranetics sells its products directly and through distributors across multiple global regions, focusing on improving outcomes in challenging cardiovascular cases. Founded in 1984 and headquartered in Colorado Springs, the company is committed to innovation in medical technology to enhance the quality of care for patients undergoing cardiovascular procedures. As of August 2017, it operates as a subsidiary of Philips Holding USA Inc.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.
Pulmologix AB is a Swedish private clinical stage company focused on developing, manufacturing, and selling an oral non-steroidal anti-asthmatic drug designed for the treatment of early onset allergic asthma. Established in 2006 and headquartered in Stockholm, the company aims to address unmet medical needs in asthma management through its innovative therapeutic approach.
iRhythm Technologies, Inc. is a digital healthcare company focused on improving the diagnosis and monitoring of cardiac arrhythmias in patients. Headquartered in San Francisco, the company provides innovative ambulatory electrocardiogram (ECG) monitoring solutions, primarily through its flagship product, the Zio service. This service utilizes a lightweight, wire-free, patch-based biosensor that patients can wear for up to 14 days, allowing for continuous heart monitoring. The Zio system integrates cloud-based data analytics and machine-learning capabilities to transform extensive heartbeat data into actionable clinical insights. By streamlining the diagnostic process, iRhythm aims to enhance patient health outcomes and reduce unnecessary healthcare expenses. Additionally, the company collaborates with Verily Life Sciences to develop advanced atrial fibrillation screening and monitoring products. Established in 2006, iRhythm continues to lead in the digital healthcare space by redefining cardiac arrhythmia diagnosis.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.
Imagen Biotech, Inc. is a private, venture-backed biopharmaceutical company focused on identifying and developing therapeutics for blinding diseases with high unmet medical needs, including dry age-related macular degeneration. Since its formation in the summer of 2011 with financing from SV Life Sciences, Novo Ventures and Fidelity Biosciences, Imagen continues to evaluate numerous compounds sourced worldwide to determine their feasibility as drug development candidates. The Company was co-founded by ophthalmologists Matthew Feinsod, MD, former medical officer at FDA and later SVP with Eyetech Pharmaceuticals, and David Guyer, MD, former founder and CEO of Eyetech Pharmaceuticals and current partner with SV Life Sciences. Imagen is funded to develop approximately three compounds through predetermined milestones.
Cianna Medical, Inc., a women’s health company, develops medical technologies for treating breast cancer. The company offers SAVI SCOUT, a wire-free radar localization solution for breast tumor localization; and SAVI Brachy, a solution to deliver a highly-precise dose of radiation only to the tissue where the cancer is likely to reoccur. It also offers BrachyBytes, an e-newsletter that features interviews with experts in breast brachytherapy. The company was incorporated in 2007 and is based in Aliso Viejo, California. As of November 13, 2018, Cianna Medical, Inc. operates as a subsidiary of Merit Medical Systems, Inc.
HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.
Funxional Therapeutics Ltd. develops pharmaceutical products in the United Kingdom. Its product candidates include BN83470 for the treatment of respiratory indications, initially asthma; BN83250 for the prevention of surgical adhesion formation and for the treatment of stroke; and FX125L, an orally available small molecule that belongs to a therapeutic class named broad spectrum chemokine inhibitors. The company also offers early stage preclinical programs that focus on Alzheimer's disease, autoimmune disorders, and pain and diabetes. Funxional Therapeutics Ltd. as founded in 2005 and is based in Cambridge, the United Kingdom.
Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.
MediQuest is a specialty pharmaceutical / biotechnology company specializing in first in class and best in class topical drug delivery systems. Primary focus is on the discovery, development, and commercialization of products for the topical treatment of inflammatory and infectious diseases.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
MediQuest is a specialty pharmaceutical / biotechnology company specializing in first in class and best in class topical drug delivery systems. Primary focus is on the discovery, development, and commercialization of products for the topical treatment of inflammatory and infectious diseases.
Funxional Therapeutics Ltd. develops pharmaceutical products in the United Kingdom. Its product candidates include BN83470 for the treatment of respiratory indications, initially asthma; BN83250 for the prevention of surgical adhesion formation and for the treatment of stroke; and FX125L, an orally available small molecule that belongs to a therapeutic class named broad spectrum chemokine inhibitors. The company also offers early stage preclinical programs that focus on Alzheimer's disease, autoimmune disorders, and pain and diabetes. Funxional Therapeutics Ltd. as founded in 2005 and is based in Cambridge, the United Kingdom.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
BioMimetic Therapeutics is a biotechnology company focused on developing biologically active drug-device combination products that stimulate the body's natural tissue regenerative processes. Founded in 1999 and headquartered in Franklin, Tennessee, the company offers a range of products targeting various orthopedic and sports medicine conditions. These include Augment Injectable and Augment Rotator Cuff, which are designed for applications such as foot and ankle fusions, wrist fracture healing, and rotator cuff tear surgical treatment. Additionally, the Augment Tendinopathy Injection addresses injuries related to tendon overuse. Through its innovative approaches, BioMimetic Therapeutics aims to improve healing outcomes for patients with skeletal and associated tissue injuries.